Crescendo Biologics, the drug developer of novel, targeted T-cell engaging therapeutics, has announced that Eva-Lotta Allan has been appointed as non-executive director of the company with immediate effect.
Allan has more than 30 years’ experience in the biopharmaceutical industry, most recently as CBO at clinical-stage T-cell receptor company, Immunocore.
During her five years at Immunocore she raised US$320 million in a Series A round, established significant strategic partnerships with top pharmaceutical companies and was elected to the board of the BIA.
She has also served on a number of other boards in both private and publicly held companies during her career and is currently a non-executive director for Targovax ASA.
Prior to Immunocore, Allan was CBO at Ablynx. At Ablynx, she closed a number of deals of significant value with premier pharmaceutical companies bringing in more than €160 million in non-dilutive cash to the company, held strategic and operational responsibilities, and contributed to its successful IPO on Euronext in 2007.
Kevin Johnson, chairman of the board of directors at Crescendo Biologics, said: “Eva Lotta adds a tremendous network and expertise in deal making as she successfully has demonstrated in her operative business development roles at Vertex, Ablynx and Immunocore. As an independent industry expert, she also brings vast experience in immuno-oncology and in the development of multi-functional biologics - an ideal combination for Crescendo.”
Allan commented: “With Crescendo’s recent $70 million Series B financing, it is in a strong position to develop its exciting pipeline of potent, multi-functional Humabody therapeutics in oncology. I look forward to working with the Crescendo team as we continue to build on the significant achievements delivered to date."
